Marinomed Biotech AG Announces Management Board Changes

Marinomed Biotech AG, a Vienna Stock Exchange-listed company, has announced significant changes to its management. CFO Pascal Schmidt is set to resign by the end of January 2025. Gabriele Ram, previously with Wienerberger AG, will temporarily manage the finance department. Ram brings over a decade of financial leadership experience from various C-Level roles in Austrian and German companies, most recently as CFO at Wienerberger Piping Solutions.

The company has also successfully completed its restructuring process. As part of this transition, the Carragelose business unit has been sold, securing Marinomed’s financial standing. CEO Andreas Grassauer expressed gratitude towards Schmidt for his contributions, particularly during the 2019 IPO and recent challenges.

Looking forward, Marinomed plans to focus on its Marinosolv technology platform. Chairman Simon Nebel also thanked Schmidt and conveyed best wishes for his future endeavors.